Cantel Medical Corp. (NYSE:CMN) Director Ann E. Berman sold 1,453 shares of Cantel Medical Corp. stock in a transaction on Friday, September 30th. The shares were sold at an average price of $77.56, for a total value of $112,694.68. Following the transaction, the director now owns 5,424 shares in the company, valued at $420,685.44. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Cantel Medical Corp. (NYSE:CMN) opened at 78.46 on Thursday. The company has a 50 day moving average price of $76.84 and a 200-day moving average price of $70.89. Cantel Medical Corp. has a one year low of $52.23 and a one year high of $81.63. The firm has a market capitalization of $3.25 billion, a PE ratio of 54.56 and a beta of 1.59.

Cantel Medical Corp. (NYSE:CMN) last announced its earnings results on Thursday, September 29th. The company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.37 by $0.11. Cantel Medical Corp. had a return on equity of 16.70% and a net margin of 9.02%. The business had revenue of $179 million for the quarter. During the same period in the previous year, the firm earned $0.39 earnings per share. The firm’s revenue was up 18.3% compared to the same quarter last year. On average, equities analysts predict that Cantel Medical Corp. will post $1.98 EPS for the current year.

Insider Buying and Selling by Quarter for Cantel Medical Corp. (NYSE:CMN)

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. LS Investment Advisors LLC increased its position in Cantel Medical Corp. by 7.5% in the second quarter. LS Investment Advisors LLC now owns 1,510 shares of the company’s stock valued at $104,000 after buying an additional 106 shares in the last quarter. ProShare Advisors LLC increased its position in Cantel Medical Corp. by 3.2% in the second quarter. ProShare Advisors LLC now owns 5,186 shares of the company’s stock valued at $356,000 after buying an additional 160 shares in the last quarter. UBS Asset Management Americas Inc. increased its position in Cantel Medical Corp. by 0.7% in the second quarter. UBS Asset Management Americas Inc. now owns 23,099 shares of the company’s stock valued at $1,588,000 after buying an additional 163 shares in the last quarter. PineBridge Investments L.P. increased its position in Cantel Medical Corp. by 3.8% in the second quarter. PineBridge Investments L.P. now owns 4,548 shares of the company’s stock valued at $312,000 after buying an additional 165 shares in the last quarter. Finally, Arizona State Retirement System increased its position in Cantel Medical Corp. by 1.1% in the second quarter. Arizona State Retirement System now owns 18,647 shares of the company’s stock valued at $1,282,000 after buying an additional 200 shares in the last quarter. 81.61% of the stock is currently owned by hedge funds and other institutional investors.

CMN has been the topic of a number of recent research reports. Benchmark Co. initiated coverage on Cantel Medical Corp. in a report on Monday, August 29th. They issued a “buy” rating and a $83.00 target price on the stock. Needham & Company LLC initiated coverage on Cantel Medical Corp. in a report on Wednesday, August 24th. They issued a “hold” rating on the stock.

Cantel Medical Corp. Company Profile

Cantel Medical Corp. is a provider of infection prevention and control products and services in the healthcare market. The Company’s segments include Endoscopy, Water Purification and Filtration, Healthcare Disposables, Dialysis and Specialty Packaging. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

5 Day Chart for NYSE:CMN

Receive News & Stock Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related stocks with our FREE daily email newsletter.